Needlefree Catheter Patency Device

See how Neutron can help you make a real difference clinically and financially.

Cost Savings Calculator

This simple-to-use calculator will help you better understand the financial impact of central line catheter occlusions on your institution. Neutron can help reduce these costs by helping to reduce the overall incidence of central line catheter occlusions.


Calculator instructions

Please enter your data in the fields below. Enter only numeric values. Click on the Calculate Savings buttons to see your results. These calculations are estimates only. Actual results may vary.

tPA and Connector Costs

Estimate based on published data
Average doses required to clear the occlusion (2 is typical)
Drug cost (Est. $80 to $100 per dose)
Nursing time
Drug admix or pharmacy time
  • Travel time (if applicable for homecare or infusion center)
  • Unscheduled nursing visit
  • Ancillary supplies
Estimate the number of connectors per central line catheter over the life of the catheter. For example: a single lumen central line catheter with a dwell time of 21 days and connectors changed every 72 hours would have 7 connectors per line.
Clear All Fields
TPA + Connector Cost Savings

Additional Clinical Costs of Catheter Occlusion

In the referenced published study, patency restoration was successful in 73.9% to 89.9% of cases.
If applicable. If non-hospital based, unreimbursed alternate site care days.
Estimate all unreimbursed expenses associated with a PICC or CVC replacement, which might include length of hospital stay, costs of un-scheduled homecare visits, supplies, physician time, etc.
Clear All Fields
Additional Clinical Cost Savings

Detailed Summary

Total tPA cost per treatment4
Percentage of central lines that require tPA2,3
Number of central line catheters placed each year1
tPA reduction using Neutron (estimated 50%)5
tPA Usage With Your Connector With Neutron
Total cost of tPA administration
Cost per connector
Total connector cost
Total cost
tPA Cost Savings Per Year Using Neutron: $0.00
Additional Clinical Costs of Catheter Occlusion With Your Connector With Neutron
Number of central line catheters placed each year1
Percentage of central lines that require tPA2,3
tPA reduction using Neutron (estimated 50%)5
Total Number of occlusions
tPA Success rate6
Number of catheter replacements
PICC/CVC replacement cost
Yearly cost of catheter replacements
Increased length of stay (in days)
Cost per day of increased stay
Total cost for increased length of stay
Yearly cost of increased length of stay
Additional Clinical Costs of Catheter Occlusion $0.00
Total Cost Savings per Year Using Neutron $0.00


  1. Haire WD, Atkinson JB, Stephen LC, Kotulak GD, et al. Urokinase versus recombinant tissue plasminogen activator in thrombosed central venous catheters: a double-blinded, randomized trial. Thromb Haemost. 1994;72(4):543-7.
  2. Deitcher S, et al. Safety and efficacy of alteplase for restoring function in occluded central venous catheters: results of the cardiovascular thrombolytic to open occluded lines trial. J Clin Oncol. 2002;20(1): 317-24.
  3. Timoney JP, Malkin MG, Leone DM, Groeger JS, Heaney ML, Keefe DL, Klang M, Lucarelli CD, Muller RJ, Eng SL, Connor M, Small TN, Brown AE, Saltz LB. Safe and cost effective use of alteplase for the clearance of occluded central venous access devices, JCO. Apr 1, 2002:1918-1922; DOI:10.1200/JCO.2002.07.131.
  4. Observational in-vivo evaluation of the Neutron™ needlefree catheter patency device and its effects on catheter occlusions in a home care setting. Study Summary. ICU Medical.
  5. Ponec D, Irwin D, Haire WD, Hill PA, Li X, McCluskey ER; COOL Investigators. Recombinant tissue plasminogen activator (alteplase) for restoration of flow in occluded central venous access devices: a double-blind placebo-controlled trial - the Cardiovascular Thrombolytic to Open Occluded Lines (COOL) efficacy trial. J Vasc Interv Radiol. 2001 Aug;12(8):951-5
  6. Kokotis K. Cost containment and infusion services. Journal of Infusion Nursing. (2005) 28(3 Suppl.), S22-S32.
  7. Cummings-Winfield C, Mushani-Kanji T. Restoring patency to central venous access devices. Clin J Oncol Nurs. 2008; 12(6):925-934.
  8. O'Grady NP, Alexander M, Dellinger EP, et al. Guidelines for the prevention of intravascular catheter-related infections. MMWR Recomm Rep. 2002;51(RR-10):1-26.
  9. The Kaiser Family Foundation "Hospital Adjusted Expenses per Inpatient Day, 2009." Data Source: AHA Annual Surveys. ©2011 by Health Forum LLC, an affiliate of the American Hospital Association.